Paxlovid for hospitalized COVID-19 patients with chronic kidney disease-Reference-Cited by-同舟云学术

Paxlovid for hospitalized COVID-19 patients with chronic kidney disease

Published:2023-08 Issue: Volume:216 Page:105659
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Cai Hong,Yan Jiayi,Liu Shang,Li Ping,Ding Li,Zhan Yaping,Lu Jiayue,Li Zhenyuan,Sun Yiwen,Zhu Mingli,Gao Yuan,Gong Xingrong,Ban Haiqun,Gu Leyi,Zhou Weibin,Wang Jieying,Mou Shan

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference29 articles.

1. Use of remdesivir in patients with COVID-19 on hemodialysis: a study of safety and tolerance;Aiswarya;Kidney Int Rep,2021

2. Kidney outcomes in long COVID;Bowe;J. Am. Soc. Nephrol.,2021

3. SARS-CoV-2 viral protein ORF3A injures renal tubules by interacting with TRIM59 to induce STAT3 activation;Cai;Mol. Ther.,2023

4. How bad is omicron? What scientists know so far;Callaway;Nature,2021

5. Center for systems Science and Engineering.COVID-19 Dashboard. Johns Hopkins University (http://coronavirus.jhu.edu/map.html).

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review;Advances in Respiratory Medicine;2024-01-18

2. Drug-drug interactions between COVID-19 drug therapies and antidepressants;Expert Opinion on Drug Metabolism & Toxicology;2023-11-30

3. Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence;Infectious Disease Reports;2023-10-25

4. In-hospital adverse outcomes and risk factors among chronic kidney disease patients infected with the omicron variant of SARS-CoV-2: a single-center retrospective study;BMC Infectious Diseases;2023-10-18